Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours

European Journal of Cancer

Volumn 41, Issue 9, 2005, Pages 1291-1299

  Mross, Klaus ^a   Drevs, Joachim ^a   Müller, Marianne ^a   Medinger, Michael ^a   Marmé, Dieter ^a   Hennig, Jürgen ^a   Morgan, Bruno ^a,b   Lebwohl, David ^a,c   Masson, Eric ^a,c   Ho, Yu Yun ^a,c   Günther, Clemens ^d   Laurent, Dirk ^d   Unger, Clemens ^d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

^d BAYER PHARMA AG   (Germany)

Author keywords

Antiangiogenesis; Colorectal; Tyrosine kinase inhibitor; Vascular endothelial growth factor; Vatalanib

Indexed keywords

ANGIOGENESIS INHIBITOR; VASCULOTROPIN INHIBITOR; VATALANIB;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ATAXIA; BILE DUCT OBSTRUCTION; BLOOD TOXICITY; BRAIN ISCHEMIA; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEASIBILITY STUDY; FEMALE; HEMATURIA; HOARSENESS; HUMAN; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTENSIVE CRISIS; LEIOMYOSARCOMA; LIVER METASTASIS; LONG TERM CARE; MALE; MEDICAL SOCIETY; MONOTHERAPY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; SAMPLE SIZE; SIDE EFFECT; SOLID TUMOR; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; SWEATING; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; TUMOR VASCULARIZATION; URINARY TRACT INFECTION; VEIN THROMBOSIS; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANALYSIS OF VARIANCE; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PHTHALAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 20444473802     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.03.005     Document Type: Article

References (22)

1. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186
2. D. Hanahan, and J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364
3. L.A. Liotta, and M.L. Stracke Tumor invasion and metastases: biochemical mechanisms Cancer Treat Res 40 1988 223 238
4. L. Holmgren, M.S. O'Reilly, and J. Folkman Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression Nat Med 1 1995 149 153
5. K. Mross Anti-angiogenesis therapy: concepts and importance of dosing schedules in clinical trials Drug Resist Updat 3 2000 223 235
6. J. Drevs, C. Laus, and M. Medinger Antiangiogenesis: current clinical data and future perspectives Onkologie 25 2002 520 527
7. F.A. Scappaticci Mechanisms and future directions for angiogenesis-based cancer therapies J Clin Oncol 20 2002 3906 3927
8. N. Ferrara, K. Houck, and L. Jakeman Molecular and biological properties of the vascular endothelial growth factor family of proteins Endocr Rev 13 1992 18 32
9. G. Neufeld, T. Cohen, and S. Gengrinovitch Vascular endothelial growth factor (VEGF) and its receptors FASEB J 13 1999 9 22
10. L.F. Brown, M. Detmar, and K. Claffey Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine EXS 79 1997 233 269
11. D.R. Senger, L. Van de Water, and L.F. Brown Vascular permeability factor (VPF, VEGF) in tumor biology Cancer Metastasis Rev 12 1993 303 324
12. J.M. Wood, G. Bold, and E. Buchdunger PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration Cancer Res 60 2000 2178 2189
13. J. Drevs, R. Muller-Driver, and C. Wittig PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging Cancer Res 62 2000 4015 4022
14. S. Green, and G.R. Weiss Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria Invest New Drugs 10 1992 239 253
15. B. Morgan, A.L. Thomas, and J. Drevs Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies J Clin Oncol 21 2003 3955 3964
16. J. Drevs, C.I. Schmidt-Gersbach, and K. Mross Soluble markers for the assessment of biologic activity with PTK787/ZK222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials Ann Oncology 16 2005 558 565
17. P. Rougier, E. Van Cutsem, and E. Bajetta Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Lancet 352 1998 1407 1412
18. R.T. Poon, S.T. Fan, and J. Wong Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches Ann Surg 238 2003 9 28
19. S.M. Sagar, G.A. Klassen, and K.D. Barclay Tumour blood flow: measurement and manipulation for therapeutic gain Cancer Treat Rev 19 1993 299 349
20. H.B. Larsson, T. Fritz-Hansen, and E. Rostrup Myocardial perfusion modeling using MRI Magn Reson Med 35 1996 716 726
21. George D, Michaelson D, Oh WK, et al. Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma [poster]. In: Presented at the 39th annual meeting of the american society of clinical oncology, Chicago (IL), May 31-June 3; 2003
22. W.K.A. Yung, H. Friedman, and C. Conrad Single-agent PTK/ZK in recurrent glioblastoma multiforme: a phase I trial [oral presentation] Proceedings of ASCO 22 2003 385